Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin in recurrent or persistent endometrial carcinoma
NCT00301964Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2006
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in endometrial carcinoma, sponsored by National Cancer Institute. Primary endpoints: Progression-free Survival Greater Than 6 Months and Objective Tumor Response. Started Mar 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00301964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00301964.